A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice

Antiviral Research

Volumn 84, Issue 1, 2009, Pages 23-30

  Zeng, Ruihong ^a   Li, Guangxue ^a,c   Ling, Shigan ^b   Zhang, Heqiu ^b   Yao, Zhiyan ^a   Xiu, Bingshui ^b   He, Feng ^b   Huang, Rui ^b   Wei, Lin ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Basic Medical Research Institute   (China)

^c Xingtai Medical College   (China)

Author keywords

Cellular immune response; Combined vaccine; Hepatitis C virus; Humoral immune response; mT + mE1

Indexed keywords

CORE PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN E1; HEPATITIS C VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; NONSTRUCTURAL PROTEIN 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMORAL IMMUNITY; IMMUNIZATION; LIVER PROTECTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TH1 CELL; VACCINE PRODUCTION; VIRUS IMMUNITY;

ANIMALS; ANTIBODIES, VIRAL; EPITOPES; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MICE; MICE, INBRED BALB C; PROTEIN ENGINEERING; VACCINES, COMBINED; VIRAL CORE PROTEINS; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS; MUS;

EID: 69249221321     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.07.011     Document Type: Article

References (55)

1. Arribillaga L., Sarobe P., Arina A., Gorraiz M., Borrás-Cuesta F., Ruiz J., Prieto J., Chen L., Melero I., and Lasarte J.J. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine 23 (2005) 3493-3499
2. Bertoletti A., and Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 38 (2003) 4-13
3. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 (2005) 946-952
4. Bukh J., Purcell R.H., and Miller R.H. Sequence analysis of the 5′ noncoding region of hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4942-4946
5. Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39 (2004) 1469-1475
6. Chang K.M., Gruener N.H., Southwood S., Sidney J., Pape G.R., Chisari F.V., and Sette A. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J. Immunol. 162 (1999) 1156-1164
7. Chang K.M., Thimme R., Melpolder J.J., Oldach D., Pemberton J., Moorhead-Loudis J., McHutchison J.G., and Alter H.J. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology 33 (2001) 267-276
8. Choo Q.L., Kuo G., Ralston R., Weiner A., Chien D., Van Nest G., Han J., Berger K., Thudium C., Kansopon J., Mcgarland J., Tabrizi A., Chine K., Moss B., Cummins B.L., Houghton M., and Muchmore E. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 1294-1298
9. Day C.L., Lauer G.M., Robbins G.K., McGovern B., Wurcel A.G., Gandhi R.T., Chung R.T., and Walker B.D. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J. Virol. 76 (2002) 12584-12595
10. Depraetere S., and Leroux-Roels G. Hepatitis C virus envelope proteins: immunogenicity in humans and their role in diagnosis and vaccine development. Viral Hepat. Rev. 5 (1999) 113-146
11. Encke J., Zu Putlitz J., Geissler M., and Wands J.R. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J. Immunol. 161 (1998) 4917-4923
12. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
13. Forns X., Payette P.J., Ma X., Satterfield W., Eder G., Mushahwar I.K., Govindarajan S., Davis H.L., Emerson S.U., Purcell R.H., and Bukh J. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 32 (2000) 618-625
14. Foster G.R. Past, present, and future hepatitis C treatments. Semin. Liver Dis. 24 (2004) 97-104
15. Gajewski T.F., and Fitch F.W. Anti-proliferative effect of IFN-c in immune regulation. I. IFN-c inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J. Immunol. 140 (1998) 4245-4252
16. Garcia J.E., Puentes A., Suarez J., Lopez R., Vera R., Rodriguez L.E., Ocampo M., Curtidor H., Guzman F., Urquiza M., and Patarrovo M.E. Hepatitis C virus (HCV) E1 and E2 protein regions that specifically bind to HepG2 cells. J. Hepatol. 36 (2002) 254-262
17. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., Murthy K.K., Rice C.M., and Walker C.M. HCV persistence and immune evasion in the absence of memory T cell help. Science 302 (2003) 659-662
18. Hakamada T., Funatsuki K., Morita H., Ugajin T., Nakamura I., Ishiko H., Matsuzaki Y., Tanaka N., and Imawari M. Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epitopes by ELISpot assay using peptides with human leukocyte antigen-A*2402-binding motifs. J. Gen. Virol. 85 (2004) 1521-1531
19. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Waqner H., Takeda K., and Akira S. A toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
20. Higashi K., Tsukiyama-Kohara K., Tanaka T., Tanaka E., Kiyosawa K., and Kohara M. Characterization of hypervariable region in hepatitis C virus envelope protein during acute and chronic infection. Arch. Virol. 150 (2005) 883-898
21. Houghton M., and Sergio A. Prospects for a vaccine against the hepatitis C virus. Nature 436 (2005) 961-966
22. Hung K., Hayashi R., Lafond-Walker A., Lowenstein C., Pardoll D., and Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188 (1998) 2357-2368
23. Johan N. Selective inhibitors of hepatitis C virus replication. Antiviral Res. 71 (2006) 363-371
24. Kato N., Ikeda M., Sugiyama K., Mizutani T., Tanaka T., and Shimotohno K. Hepatitis C virus population dynamics in human lymphocytes and hepatocytes infected in vitro. J. Gen. Virol. 79 (1998) 1859-1869
25. Keene J.A., and Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155 (1982) 768-782
26. Kurokohchi K., Arima K., and Nishioka M. A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection. J. Hepatol. 34 (2001) 930-935
27. Lanford R.E., Guerra B., Chavez D., Bigger C., Brasky K.M., Wang X.H., Ray S.C., and Thomas D.L. Cross-genotype immunity to hepatitis C virus. J. Virol. 78 (2004) 1575-1581
28. Lauer G.M., Barnes E., Lucas M., Timm J., Ouchi K., Kim A.Y., Day C.L., Robbins G.K., Casson D.R., Reiser M., Dusheiko G., Allen T.M., Chung R.T., Walker B.D., and Klenerman P. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127 (2004) 924-936
29. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., Dohrenwend P., Robbins G., Phillips R., Klenerman P., and Walker B.D. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191 (2000) 1499-1512
30. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
31. Maertens G., and Stuyver L. Genotypes and genetic variation of hepatitis C virus. In: Zuckerman A., Harrison T., James K., and Morris A. (Eds). Molecular Medicine of Hepatitis. Molecular Medical Science Series (1997), Wiley, Chichester, UK 183-233
32. Mitchison N.A. The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation. Eur. J. Immunol. 1 (1971) 18-27
33. Nakamoto Y., Kaneko S., Takizawa H., Kikumoto Y., Takano M., Himeda Y., and Kobayashi K. Analysis of the CD8-positive T cell response in Japanese patients with chronic hepatitis C using HLA-A*2402 peptide tetramers. J. Med. Virol. 70 (2003) 51-61
34. Panuska J.R., Merolla R., Rebert N.A., Hoffmann S.P., Tsivitse P., Cirino N.M., Silverman R.H., and Rankin J.A. Respiratory syncytial virus induces interleukin-10 by human alveolar macrophages. Suppression of early cytokine production and implications for incomplete immunity. J. Clin. Invest. 96 (1995) 2445-2453
35. Perrine M., and Geneviève I. Hepatitis C vaccines. Drug Discov. Today: Ther. Strateg. 3 (2006) 203-209
36. Ray S.C., Wang Y.M., Laeyendecker O., Ticehurst J.R., Villano S.A., and Thomas D.L. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J. Virol. 73 (1999) 2938-2946
37. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5 (2005) 215-229
38. Rosen H.R., Miner C., Lewinsohn D., Sasaki A.W., Conrad A.J., Bakke A., and Bouwer A. Determination of Hepatitis C virus-specific effector CD4+ T cell by flow cytometry: correlation with clinical disease stages. Hepatology 35 (2002) 190-198
39. Schulzezur W.J., Schmitz H., Borowski E., and Borowski P. The proteins of the Hepatitis C virus: their features and interactions with intracellular protein phosphorylation. Arch. Virol. 148 (2003) 1247-1267
40. Shoukry N.H., Grakoui A., Houghton M., Chien D.Y., Ghrayeb J., Reimann K.A., and Walker C.M. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197 (2003) 1645-1655
41. Shoukry N.H., Cawthon A.G., and Walker C.M. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu. Rev. Microbiol. 58 (2004) 391-424
42. Sieling P.A., Abrams J.S., Yamamura M., Salgame P., Bloom B.R., Rea T.H., and Modlin R.L. Immunosuppressive roles for IL-10 and IL-4 in human infection. In vitro modulation of T-cell responses in leprosy. J. Immunol. 150 (1993) 5501-5510
43. Simon B.E., Comell K.A., Clark T.R., Chou S., Rosen H.R., and Barry R.A. DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein. Infect. Immun. 71 (2003) 6372-6380
44. Smyk-Pearson S., Tester I.A., Lezotte D., Sasaki A.W., Lewinsohn D.M., and Rosen H.R. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J. Infect. Dis. 194 (2006) 454-463
45. Song X.G., Ling S.G., Zhang H.Q., Chen K., Sun K., and Zhu C.X. Construction of prokaryotic expression vector (pBVIL1) and using it in the expression of antigens of hepatitis C virus. J. Cell. Mol. Immunol. 17 (2001) 231-235
46. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., and Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194 (2001) 1395-1406
47. Tokita H., Okamoto H., Tsuda F., Song P., Nakata S., Chosa T., Iizuka H., Mishiro S., Miyakawa Y., and Mayumi M. Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 11022-11026
48. Torresi J., Bharadwaj M., Lackson D.C., and Gowans E.J. Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventive vaccine strategy. Curr. Drug Targets 5 (2004) 41-56
49. Triyatni M., Saunier B., Maruvada P., Davis A.R., Ulianich L., Heller T., Patel A., Kohn L.D., and Liang T.J. Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J. Virol. 76 (2002) 9335-9344
50. Vertuani S., Bazzaro M., Gualandi G., Micheletti F., Marastoni M., Fortini C., Canella A., Marino M., Tomatis R., Traniello S., and Gavioli R. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur. J. Immunol. 32 (2002) 144-154
51. Ward S., Lauer G., Isba R., Walker B., and Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base. Clin. Exp. Immunol. 128 (2002) 195-203
52. + T cells in chronic hepatitis C virus infection. J. Immunol. 169 (2002) 3447-3458
53. Wertheimer A.M., Miner C., Lewinsohn D.M., Sasaki A.W., Kaufman E., and Rosen H.R. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 37 (2003) 577-589
54. Yan J.Q., Ling S.G., Liu H., Zhang H.Q., Song X.G., Xiu B.S., Chen K., Wang G., and Zhu C. Induction of strong cytotoxic T-lymphocyte responses to hepatitis C virus with recombinant poly-epitope in BALB/c mice. Virol. Immunol. 19 (2006) 64-73
55. Zhu F.L., Yang M.Y., and Eckels. Interactions between helper T-cell epitopes of hepatitis C virus. Vaccine 23 (2005) 3572-3580